Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C25H17F3N4O3.3C4H4O4 |
Molecular Weight | 1305.0619 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 3 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.[H][C@]12OC3=CC=C(OC4=CC=NC5=C4CCC(=O)N5)C=C3[C@@]1([H])[C@@H]2C6=NC7=C(N6)C=C(C=C7)C(F)(F)F.[H][C@]89OC%10=CC=C(OC%11=CC=NC%12=C%11CCC(=O)N%12)C=C%10[C@@]8([H])[C@@H]9C%13=NC%14=C(N%13)C=C(C=C%14)C(F)(F)F
InChI
InChIKey=CETNPISTLYWCDC-SWWFIDOGSA-N
InChI=1S/2C25H17F3N4O3.3C4H4O4/c2*26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23;3*5-3(6)1-2-4(7)8/h2*1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33);3*1-2H,(H,5,6)(H,7,8)/b;;3*2-1-/t2*20-,21-,22-;;;/m00.../s1
Molecular Formula | C25H17F3N4O3 |
Molecular Weight | 478.4227 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Lifirafenib (BGB-283 or BEIGENE-283), a dual inhibitor targeting BRAF kinase and EGFR, was studied for the treatment of different cancer types harboring mutations in BRAF, KRAS, and NRAS. Lifirafenib participates in Phase II clinical trial in combination with PD-0325901 to treat the patients with solid tumor.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5145 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26208524 |
32.0 nM [IC50] | ||
Target ID: CHEMBL1169596 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26208524 |
5.6 nM [IC50] | ||
Target ID: CHEMBL2363049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26208524 |
29.0 nM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03905148
BGB-283 (lifirafenib) 5 or mg once a day
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:20:43 UTC 2023
by
admin
on
Sat Dec 16 14:20:43 UTC 2023
|
Record UNII |
9VU33DC00T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C174591
Created by
admin on Sat Dec 16 14:20:43 UTC 2023 , Edited by admin on Sat Dec 16 14:20:43 UTC 2023
|
PRIMARY | |||
|
300000011158
Created by
admin on Sat Dec 16 14:20:43 UTC 2023 , Edited by admin on Sat Dec 16 14:20:43 UTC 2023
|
PRIMARY | |||
|
9VU33DC00T
Created by
admin on Sat Dec 16 14:20:43 UTC 2023 , Edited by admin on Sat Dec 16 14:20:43 UTC 2023
|
PRIMARY | |||
|
1854985-74-2
Created by
admin on Sat Dec 16 14:20:43 UTC 2023 , Edited by admin on Sat Dec 16 14:20:43 UTC 2023
|
PRIMARY | |||
|
135395339
Created by
admin on Sat Dec 16 14:20:43 UTC 2023 , Edited by admin on Sat Dec 16 14:20:43 UTC 2023
|
PRIMARY | |||
|
FG-150
Created by
admin on Sat Dec 16 14:20:43 UTC 2023 , Edited by admin on Sat Dec 16 14:20:43 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |